ChemoCentryx is a biopharmaceutical company developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of our drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. The Company's drug candidates are small molecules, which are orally administered, offering significant quality of life benefits, since patients swallow a capsule or pill instead of having to visit a clinic for an infusion or undergo an injection.
Type | Public | |
Founded | 1997 | |
HQ | Mountain View, US | Map |
Website | chemocentryx.com | |
Employee Ratings | More |
USD | |
---|---|
Net income (Q3, 2018) | (10.9m) |
EBIT (Q3, 2018) | (11.5m) |
Market capitalization (15-Feb-2019) | 572.0m |
Closing stock price (15-Feb-2019) | 11.0 |
Cash (30-Sep-2018) | 24.1m |
EV | 562.6m |
USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 2.8m | 4.3m | 8.2m | 8.9m | 9.0m | 9.5m | ||||||||||
General and administrative expense | 2.9m | 3.5m | 3.4m | 3.5m | 3.7m | 3.6m | 3.8m | 4.1m | 3.9m | 3.2m | 4.6m | 4.2m | 3.6m | 4.7m | 4.7m | 5.4m |
R&D expense | 8.2m | 8.1m | 9.0m | 7.5m | 8.4m | 8.6m | 7.9m | 11.2m | 9.1m | 8.4m | 10.0m | 14.3m | 12.3m | 14.7m | 17.8m | 15.1m |
Operating expense total | 11.1m | 11.7m | 12.4m | 11.1m | 12.1m | 12.2m | 11.7m | 15.3m | 12.9m | 11.6m | 14.5m | 18.5m | 15.9m | 19.4m | 22.5m | 20.5m |
USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 22.3m | 11.6m | 13.1m | 20.9m | 25.4m | 11.6m | 14.6m | 13.4m | 21.9m | 13.9m | 19.0m | 21.5m | 18.0m | 30.6m | 68.8m | 24.1m |
Accounts Receivable | 175.0k | 120.0k | 30.2m | 218.0k | 530.0k | 1.7m | 164.0k | 336.0k | ||||||||
Inventories | 1.3m | |||||||||||||||
Current Assets | 125.6m | 133.7m | 100.8m | 86.1m | 76.1m | 71.4m | 74.2m | 65.2m | 127.0m | 122.7m | 119.9m | 124.2m | 122.4m | 149.8m | 184.9m | 176.1m |
USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (29.1m) | (11.5m) | (12.3m) | (34.7m) | (12.0m) | (24.1m) | (11.6m) | (15.2m) | (25.2m) | (32.3m) | (6.0m) | (15.2m) | (21.8m) | (9.4m) | (16.3m) | (27.2m) |
Depreciation and Amortization | 426.0k | 153.0k | 414.0k | 259.0k | 86.0k | 173.0k | 260.0k | 203.0k | 311.0k | 111.0k | 227.0k | 371.0k | ||||
Inventories | 1.3m | |||||||||||||||
Accounts Payable | (58.0k) | (199.0k) | 690.0k | 121.0k | 809.0k | 280.0k | 615.0k | 619.0k | (162.0k) | 165.0k | 819.0k | 704.0k | 682.0k | (951.0k) | (378.0k) | (824.0k) |
USD | Y, 2018 |
---|---|
EV/EBIT | -48.8 x |
EV/CFO | 17.7 x |
Debt/Equity | 0.7 x |
Debt/Assets | 0.1 x |
Financial Leverage | 8.9 x |
When was ChemoCentryx founded?
ChemoCentryx was founded in 1997.
Who are ChemoCentryx key executives?
ChemoCentryx's key executives are Thomas J. Schall and Markus J. Cappel.
How many employees does ChemoCentryx have?
ChemoCentryx has 66 employees.
What is ChemoCentryx revenue?
Latest ChemoCentryx annual revenue is $82.5 m.
What is ChemoCentryx revenue per employee?
Latest ChemoCentryx revenue per employee is $1.2 m.
Who are ChemoCentryx competitors?
Competitors of ChemoCentryx include Biogen, MyoKardia and Athersys.
Where is ChemoCentryx headquarters?
ChemoCentryx headquarters is located at 850 Maude Avenue, Mountain View.
Where are ChemoCentryx offices?
ChemoCentryx has an office in Mountain View.
How many offices does ChemoCentryx have?
ChemoCentryx has 1 office.